{"entity":{"id":"pheast-therapeutics","kind":"company","name":"Pheast Therapeutics","aka":[],"tldr":"Pheast Therapeutics makes an antibody that removes a 'don't eat me' signal, CD24, that cancer cells use to hide from macrophages, immune cells that swallow and destroy them. It is in a first trial in advanced solid tumours.","summary":"Pheast Therapeutics, a private company in Redwood City, California, was co-founded from the Stanford laboratory of Irv Weissman, with Ravi Majeti among its cofounders and Roy Maute as cofounder and chief executive, building on the 2019 Nature report that CD24 acts as a macrophage 'don't eat me' signal in ovarian and breast cancer. Its lead PHST001 is an anti-CD24 antibody in a phase 1 trial (NCT06840886) of up to 80 patients with advanced solid tumours, alone and with chemotherapy or mirvetuximab soravtansine in cohorts including ovarian, endometrial and biliary cancer; the first patient was treated in April 2025 and initial phase 1a data were reported at AACR 2026. It is also developing PHST677, a bispecific ADC targeting CDH1 and Nectin-4. Its first registered cancer trial, NCT06840886, was posted on ClinicalTrials.gov in February 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.pheast.com/"},{"label":"First patient treated, April 2025","url":"https://www.pheast.com/news/pheast-therapeutics-announces-first-patient-treated-in-phase-1-clinical-trial-of-phst001-for-patients-with-advanced-solid-tumors"},{"label":"Initial phase 1a data at AACR 2026","url":"https://www.pheast.com/news/pheast-therapeutics-reports-initial-phase-1a-data-showing-early-clinical-activity-and-target-engagement-for-phst001-at-aacr-2026"},{"label":"ClinicalTrials.gov: phase 1 trial of PHST001 (NCT06840886)","url":"https://clinicaltrials.gov/study/NCT06840886"}],"tags":[],"related":[],"cancers":["ovarian","endometrial","cholangiocarcinoma"],"sections":["immunotherapy"],"technologies":["monoclonal-antibody","checkpoint-inhibitor"],"targets":["cd24"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the pages read on 29 October 2026.","No financing round is recorded because no release with an amount was read.","The AACR 2026 data were described by the company as showing early clinical activity; the numbers were not read."],"hq":"Redwood City, CA","country":"US","companyType":"biotech","website":"https://www.pheast.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/pheast-therapeutics/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"cd24","kind":"target","name":"CD24","route":"/targets/cd24/"}]}}